Comparative study of CEA and CA19-9 in esophageal, gastric and colon cancers individually and in combination (ROC curve analysis)

To determine the clinical serum levels of carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9), individually and in combination, for the diagnosis of 50 healthy subjects and 150 cases of esophageal, gastric, and colon cancers. The sensitivities of the two markers were compared indiv...

Full description

Saved in:
Bibliographic Details
Published inCancer biology & medicine Vol. 10; no. 3; pp. 148 - 157
Main Authors Bagaria, Bhawna, Sood, Sadhna, Sharma, Rameshwaram, Lalwani, Soniya
Format Journal Article
LanguageEnglish
Published China Department of Biochemistry, S.M.S. Medical College & Hospital, Jaipur 302004, India%Department of Radiotherapy and 0ncology, S.M.S. Medical College&Hospital, Jaipur 302004, India%Advanced Bioinformatics Centre, Birla Institute of Scientific Research, Jaipur 302004, India 01.09.2013
Chinese Anti-Cancer Association
China Anti-Cancer Association
Subjects
Online AccessGet full text
ISSN2095-3941
2095-3941
DOI10.7497/j.issn.2095-3941.2013.03.005

Cover

Loading…
Abstract To determine the clinical serum levels of carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9), individually and in combination, for the diagnosis of 50 healthy subjects and 150 cases of esophageal, gastric, and colon cancers. The sensitivities of the two markers were compared individually and in combination, with specificity set at 100%. Receiver operating characteristic (ROC) curves were plotted. Serum CEA levels were significantly higher in cancer patients than in the control group. The sensitivity of CEA was determined: in esophageal cancer, sensitivity=28%, negative predictive value (NPV)=61.72%, and AUC=0.742 
(SE=0.05), with a significance level of P<0.0001; in gastric cancer, sensitivity=30%, NPV=58.82%, and AUC=0.734 (SE=0.05), with a significance level of P<0.0001; in colon cancer, sensitivity=74%, NPV=79.36%, and AUC=0.856 
(SE=0.04), with a significance level of P<0.0001. The sensitivity of CA19-9 was also evaluated: in esophageal cancer, sensitivity=18%, NPV=54.94%, and AUC=0.573 (SE =0.05), with a significance level of P=0.2054. In gastric cancer, sensitivity=42%, NPV=63.29%, and AUC=0.679 (SE =0.05), with a significance level of P<0.0011. In colon cancer, sensitivity=26%, NPV=57.47%, and AUC=0.580 (SE =0.05), with a significance level of P=0.1670. The following were the sensitivities of CEA/CA19-9 combined: in esophageal cancer, sensitivity=42%, NPV=63.29%, SE=0.078 (95% CI: 0.0159-0.322); gastric cancer, sensitivity=58%, NPV=70.42%, SE=0.072 (95% CI: -0.0866-0.198); and colon cancer, sensitivity=72%, NPV=78.12%, SE=0.070 (95% CI: 0.137-0.415). CEA exhibited the highest sensitivity for colon cancer, and CA19-9 exhibited the highest sensitivity for gastric cancer. Combined analysis indicated an increase in diagnostic sensitivity in esophageal and gastric cancer compared with that in colon cancer.
AbstractList Objective:To determine the clinical serum levels of carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9), individually and in combination, for the diagnosis of 50 healthy subjects and 150 cases of esophageal, gastric, and colon cancers. Methods:The sensitivities of the two markers were compared individually and in combination, with specificity set at 100%. Receiver operating characteristic (ROC) curves were plotted. Results:Serum CEA levels were significantly higher in cancer patients than in the control group. The sensitivity of CEA was determined:in esophageal cancer, sensitivity=28%, negative predictive value (NPV)=61.72%, and AUC=0.742 (SE=0.05), with a significance level of P<0.0001;in gastric cancer, sensitivity=30%, NPV=58.82%, and AUC=0.734 (SE=0.05), with a significance level of P<0.0001;in colon cancer, sensitivity=74%, NPV=79.36%, and AUC=0.856 (SE=0.04), with a significance level of P<0.0001. The sensitivity of CA19-9 was also evaluated:in esophageal cancer, sensitivity=18%, NPV=54.94%, and AUC=0.573 (SE=0.05), with a significance level of P=0.2054. In gastric cancer, sensitivity=42%, NPV=63.29%, and AUC=0.679 (SE=0.05), with a significance level of P<0.0011. In colon cancer, sensitivity=26%, NPV=57.47%, and AUC=0.580 (SE=0.05), with a significance level of P=0.1670. The following were the sensitivities of CEA/CA19-9 combined:in esophageal cancer, sensitivity=42%, NPV=63.29%, SE=0.078 (95%CI:0.0159-0.322);gastric cancer, sensitivity=58%, NPV=70.42%, SE=0.072 (95%CI:-0.0866-0.198);and colon cancer, sensitivity=72%, NPV=78.12%, SE=0.070 (95%CI:0.137-0.415). Conclusion:CEA exhibited the highest sensitivity for colon cancer, and CA19-9 exhibited the highest sensitivity for gastric cancer. Combined analysis indicated an increase in diagnostic sensitivity in esophageal and gastric cancer compared with that in colon cancer.
To determine the clinical serum levels of carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9), individually and in combination, for the diagnosis of 50 healthy subjects and 150 cases of esophageal, gastric, and colon cancers.OBJECTIVETo determine the clinical serum levels of carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9), individually and in combination, for the diagnosis of 50 healthy subjects and 150 cases of esophageal, gastric, and colon cancers.The sensitivities of the two markers were compared individually and in combination, with specificity set at 100%. Receiver operating characteristic (ROC) curves were plotted.METHODSThe sensitivities of the two markers were compared individually and in combination, with specificity set at 100%. Receiver operating characteristic (ROC) curves were plotted.Serum CEA levels were significantly higher in cancer patients than in the control group. The sensitivity of CEA was determined: in esophageal cancer, sensitivity=28%, negative predictive value (NPV)=61.72%, and AUC=0.742 
(SE=0.05), with a significance level of P<0.0001; in gastric cancer, sensitivity=30%, NPV=58.82%, and AUC=0.734 (SE=0.05), with a significance level of P<0.0001; in colon cancer, sensitivity=74%, NPV=79.36%, and AUC=0.856 
(SE=0.04), with a significance level of P<0.0001. The sensitivity of CA19-9 was also evaluated: in esophageal cancer, sensitivity=18%, NPV=54.94%, and AUC=0.573 (SE =0.05), with a significance level of P=0.2054. In gastric cancer, sensitivity=42%, NPV=63.29%, and AUC=0.679 (SE =0.05), with a significance level of P<0.0011. In colon cancer, sensitivity=26%, NPV=57.47%, and AUC=0.580 (SE =0.05), with a significance level of P=0.1670. The following were the sensitivities of CEA/CA19-9 combined: in esophageal cancer, sensitivity=42%, NPV=63.29%, SE=0.078 (95% CI: 0.0159-0.322); gastric cancer, sensitivity=58%, NPV=70.42%, SE=0.072 (95% CI: -0.0866-0.198); and colon cancer, sensitivity=72%, NPV=78.12%, SE=0.070 (95% CI: 0.137-0.415).RESULTSSerum CEA levels were significantly higher in cancer patients than in the control group. The sensitivity of CEA was determined: in esophageal cancer, sensitivity=28%, negative predictive value (NPV)=61.72%, and AUC=0.742 
(SE=0.05), with a significance level of P<0.0001; in gastric cancer, sensitivity=30%, NPV=58.82%, and AUC=0.734 (SE=0.05), with a significance level of P<0.0001; in colon cancer, sensitivity=74%, NPV=79.36%, and AUC=0.856 
(SE=0.04), with a significance level of P<0.0001. The sensitivity of CA19-9 was also evaluated: in esophageal cancer, sensitivity=18%, NPV=54.94%, and AUC=0.573 (SE =0.05), with a significance level of P=0.2054. In gastric cancer, sensitivity=42%, NPV=63.29%, and AUC=0.679 (SE =0.05), with a significance level of P<0.0011. In colon cancer, sensitivity=26%, NPV=57.47%, and AUC=0.580 (SE =0.05), with a significance level of P=0.1670. The following were the sensitivities of CEA/CA19-9 combined: in esophageal cancer, sensitivity=42%, NPV=63.29%, SE=0.078 (95% CI: 0.0159-0.322); gastric cancer, sensitivity=58%, NPV=70.42%, SE=0.072 (95% CI: -0.0866-0.198); and colon cancer, sensitivity=72%, NPV=78.12%, SE=0.070 (95% CI: 0.137-0.415).CEA exhibited the highest sensitivity for colon cancer, and CA19-9 exhibited the highest sensitivity for gastric cancer. Combined analysis indicated an increase in diagnostic sensitivity in esophageal and gastric cancer compared with that in colon cancer.CONCLUSIONCEA exhibited the highest sensitivity for colon cancer, and CA19-9 exhibited the highest sensitivity for gastric cancer. Combined analysis indicated an increase in diagnostic sensitivity in esophageal and gastric cancer compared with that in colon cancer.
To determine the clinical serum levels of carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9), individually and in combination, for the diagnosis of 50 healthy subjects and 150 cases of esophageal, gastric, and colon cancers. The sensitivities of the two markers were compared individually and in combination, with specificity set at 100%. Receiver operating characteristic (ROC) curves were plotted. Serum CEA levels were significantly higher in cancer patients than in the control group. The sensitivity of CEA was determined: in esophageal cancer, sensitivity=28%, negative predictive value (NPV)=61.72%, and AUC=0.742 
(SE=0.05), with a significance level of P<0.0001; in gastric cancer, sensitivity=30%, NPV=58.82%, and AUC=0.734 (SE=0.05), with a significance level of P<0.0001; in colon cancer, sensitivity=74%, NPV=79.36%, and AUC=0.856 
(SE=0.04), with a significance level of P<0.0001. The sensitivity of CA19-9 was also evaluated: in esophageal cancer, sensitivity=18%, NPV=54.94%, and AUC=0.573 (SE =0.05), with a significance level of P=0.2054. In gastric cancer, sensitivity=42%, NPV=63.29%, and AUC=0.679 (SE =0.05), with a significance level of P<0.0011. In colon cancer, sensitivity=26%, NPV=57.47%, and AUC=0.580 (SE =0.05), with a significance level of P=0.1670. The following were the sensitivities of CEA/CA19-9 combined: in esophageal cancer, sensitivity=42%, NPV=63.29%, SE=0.078 (95% CI: 0.0159-0.322); gastric cancer, sensitivity=58%, NPV=70.42%, SE=0.072 (95% CI: -0.0866-0.198); and colon cancer, sensitivity=72%, NPV=78.12%, SE=0.070 (95% CI: 0.137-0.415). CEA exhibited the highest sensitivity for colon cancer, and CA19-9 exhibited the highest sensitivity for gastric cancer. Combined analysis indicated an increase in diagnostic sensitivity in esophageal and gastric cancer compared with that in colon cancer.
Author Sood, Sadhna
Lalwani, Soniya
Sharma, Rameshwaram
Bagaria, Bhawna
AuthorAffiliation Department of Biochemistry, S.M.S. Medical College & Hospital, Jaipur 302004, India%Department of Radiotherapy and 0ncology, S.M.S. Medical College&Hospital, Jaipur 302004, India%Advanced Bioinformatics Centre, Birla Institute of Scientific Research, Jaipur 302004, India
AuthorAffiliation_xml – name: Department of Biochemistry, S.M.S. Medical College & Hospital, Jaipur 302004, India%Department of Radiotherapy and 0ncology, S.M.S. Medical College&Hospital, Jaipur 302004, India%Advanced Bioinformatics Centre, Birla Institute of Scientific Research, Jaipur 302004, India
Author_xml – sequence: 1
  givenname: Bhawna
  surname: Bagaria
  fullname: Bagaria, Bhawna
  organization: Department of Biochemistry, S.M.S. Medical College & Hospital, Jaipur 302004, India
– sequence: 2
  givenname: Sadhna
  surname: Sood
  fullname: Sood, Sadhna
  organization: Department of Biochemistry, S.M.S. Medical College & Hospital, Jaipur 302004, India
– sequence: 3
  givenname: Rameshwaram
  surname: Sharma
  fullname: Sharma, Rameshwaram
  organization: Department of Radiotherapy and Oncology, S.M.S. Medical College & Hospital, Jaipur 302004, India
– sequence: 4
  givenname: Soniya
  surname: Lalwani
  fullname: Lalwani, Soniya
  organization: Advanced Bioinformatics Centre, Birla Institute of Scientific Research, Jaipur 302004, India
BackLink https://www.ncbi.nlm.nih.gov/pubmed/24379990$$D View this record in MEDLINE/PubMed
BookMark eNpVkVFrHCEQx6WkNOk1X6HsQx8S6F51dXf1pXAsaRsIBEr7LLPqbjw8veruhctbv3nNXRoSERxmxt__r_MenfjgDUKfCF62TLRf1kubkl9WWNQlFYzkiNAlzhvXb9DZc_7kRXyKzlNa47w4pw3j79BpxWgrhMBn6G8XNluIMNmdKdI0630RhqK7WhXgddGtiChFYX1hUtjewWjAfS5GSFO06tChggu-UOCViSk3aruzegbn9odyvqnCprc-C-S-i5-3XaHmmLXAg9snmy4_oLcDuGTOn84F-v3t6lf3o7y5_X7drW5KXXHCyp73rOZNSwETaI0yVAjN24GrXigiOGMNrxSAwKRtBtMQBhUIbZhmNYH84AW6PnJ1gLXcRruBuJcBrDwkQhwlxMkqZ2StheDDoHFNDVMGekJUS0U9tDXvm2HIrK9H1nbuN0Yr46cI7hX0dcXbOzmGnaS8wZThDLg8Au7BD-BHuQ5zzD-S5MP44JyS5nGwmGL8aPziSSyGP7NJk9zYpIxz4E2YkyRM4JZykd0u0MeXvp4N_Z83_QevgrLA
ContentType Journal Article
Copyright Copyright © Wanfang Data Co. Ltd. All Rights Reserved.
2013 Cancer Biology & Medicine 2013 Cancer Biology & Medicine
Copyright_xml – notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved.
– notice: 2013 Cancer Biology & Medicine 2013 Cancer Biology & Medicine
DBID NPM
7X8
2B.
4A8
92I
93N
PSX
TCJ
5PM
DOA
DOI 10.7497/j.issn.2095-3941.2013.03.005
DatabaseName PubMed
MEDLINE - Academic
Wanfang Data Journals - Hong Kong
WANFANG Data Centre
Wanfang Data Journals
万方数据期刊 - 香港版
China Online Journals (COJ)
China Online Journals (COJ)
PubMed Central (Full Participant titles)
Directory of Open Access Journals
DatabaseTitle PubMed
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic

PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2095-3941
EndPage 157
ExternalDocumentID oai_doaj_org_article_5d998ffd053e4ceab11c7395f758b6ff
PMC3860340
zgzllc_e201303004
24379990
Genre Journal Article
GroupedDBID -05
-0E
-SE
-S~
5VR
8FE
8FH
92F
92I
92M
9D9
9DE
AAKDD
ABDBF
ABKZE
ABUWG
ACUHS
ADRAZ
AFKRA
AFUIB
ALMA_UNASSIGNED_HOLDINGS
BBNVY
BENPR
BHPHI
BPHCQ
BVBZV
CAJEE
CCEZO
CCPQU
CHBEP
CIEJG
DIK
EBD
EOJEC
ESX
GROUPED_DOAJ
HCIFZ
HYE
JUIAU
KQ8
LK8
M48
M7P
MET
NPM
OBODZ
OK1
PGMZT
PHGZM
PHGZT
PIMPY
PQGLB
PQQKQ
PROAC
Q--
Q-4
RNS
RPM
RT5
S..
T8U
TCJ
TGQ
U1F
U1G
U5E
U5O
WFFXF
~N8
7X8
2B.
4A8
93N
FA0
PMFND
PSX
R-E
5PM
PUEGO
ID FETCH-LOGICAL-d2814-b8b458673a01a7ece399d87f8cb9c19844682caa90176fe614a2a9de4d451a243
IEDL.DBID M48
ISSN 2095-3941
IngestDate Wed Aug 27 01:31:22 EDT 2025
Thu Aug 21 14:04:51 EDT 2025
Thu May 29 04:01:23 EDT 2025
Fri Jul 11 12:08:29 EDT 2025
Mon Jul 21 06:01:43 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords Carcinoembryonic antigen
Receiver operating characteristic curve
carbohydrate antigen 19-9, human
sensitivity and specificity
carbohydrate antigen 19-9,human
Language English
License This work is licensed under a Creative Commons Attribution 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by/3.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-d2814-b8b458673a01a7ece399d87f8cb9c19844682caa90176fe614a2a9de4d451a243
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Correspondence to: Bhawna Bagaria
E-mail: bhawna_bagaria@yahoo.com
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.7497/j.issn.2095-3941.2013.03.005
PMID 24379990
PQID 1490738905
PQPubID 23479
PageCount 10
ParticipantIDs doaj_primary_oai_doaj_org_article_5d998ffd053e4ceab11c7395f758b6ff
pubmedcentral_primary_oai_pubmedcentral_nih_gov_3860340
wanfang_journals_zgzllc_e201303004
proquest_miscellaneous_1490738905
pubmed_primary_24379990
PublicationCentury 2000
PublicationDate 2013-09-00
PublicationDateYYYYMMDD 2013-09-01
PublicationDate_xml – month: 09
  year: 2013
  text: 2013-09-00
PublicationDecade 2010
PublicationPlace China
PublicationPlace_xml – name: China
PublicationTitle Cancer biology & medicine
PublicationTitleAlternate Cancer Biol Med
PublicationTitle_FL Cancer Biology & Medicine
PublicationYear 2013
Publisher Department of Biochemistry, S.M.S. Medical College & Hospital, Jaipur 302004, India%Department of Radiotherapy and 0ncology, S.M.S. Medical College&Hospital, Jaipur 302004, India%Advanced Bioinformatics Centre, Birla Institute of Scientific Research, Jaipur 302004, India
Chinese Anti-Cancer Association
China Anti-Cancer Association
Publisher_xml – name: Department of Biochemistry, S.M.S. Medical College & Hospital, Jaipur 302004, India%Department of Radiotherapy and 0ncology, S.M.S. Medical College&Hospital, Jaipur 302004, India%Advanced Bioinformatics Centre, Birla Institute of Scientific Research, Jaipur 302004, India
– name: Chinese Anti-Cancer Association
– name: China Anti-Cancer Association
References 22387886 - Eur J Gastroenterol Hepatol. 2012 Jun;24(6):605-12
11154168 - J Clin Gastroenterol. 2001 Jan;32(1):41-4
11984734 - Gastric Cancer. 2000 Dec;3(4):177-186
11957811 - Pol Merkur Lekarski. 2002 Jan;12(67):77-80
19413512 - Annu Rev Biomed Eng. 2009;11:177-202
18942720 - J Surg Oncol. 2009 Jan 1;99(1):65-70
19579599 - Hepatogastroenterology. 2009 Mar-Apr;56(90):361-6
21332006 - Turk J Gastroenterol. 2010 Dec;21(4):461-3
18439085 - Asian Pac J Cancer Prev. 2008 Jan-Mar;9(1):97-100
12237895 - Int J Cancer. 2002 Oct 20;101(6):545-8
19688060 - Cancer Res Treat. 2008 Mar;40(1):16-21
16033052 - Anticancer Res. 2005 May-Jun;25(3A):1507-15
16100946 - Cancer Invest. 2005;23(4):338-51
22810477 - Dis Colon Rectum. 2012 Aug;55(8):900-6
18821070 - Adv Ther. 2008 Oct;25(10):1075-84
15627885 - Tumour Biol. 2004 Sep-Dec;25(5-6):228-34
15383868 - World J Surg. 2004 Jul;28(7):680-5
8903494 - Eur J Surg Oncol. 1996 Oct;22(5):505-7
18375392 - J Biol Chem. 2008 Jun 6;283(23):15647-55
20396541 - Cancer Res Treat. 2004 Jun;36(3):178-81
12118264 - Rev Hosp Clin Fac Med Sao Paulo. 2002 May-Jun;57(3):89-92
10678558 - Jpn J Clin Oncol. 1999 Nov;29(11):550-5
8472349 - Clin Chem. 1993 Apr;39(4):561-77
14575569 - Zhonghua Zhong Liu Za Zhi. 2003 Sep;25(5):457-60
1603581 - Orv Hetil. 1992 May 24;133(21):1301-4, 1307
11274010 - Clin Chem. 2001 Apr;47(4):624-30
15362797 - Hepatogastroenterology. 2004 Sep-Oct;51(59):1544-7
2369087 - Anticancer Res. 1990 May-Jun;10(3):703-8
8869281 - J Pathol. 1996 Aug;179(4):358-69
11819806 - World J Gastroenterol. 2001 Jun;7(3):431-4
14520526 - Gastric Cancer. 2003;6(3):142-5
7690061 - Int J Biol Markers. 1993 Apr-Jun;8(2):88-93
14605576 - Dis Colon Rectum. 2003 Nov;46(11):1538-44
References_xml – reference: 12237895 - Int J Cancer. 2002 Oct 20;101(6):545-8
– reference: 21332006 - Turk J Gastroenterol. 2010 Dec;21(4):461-3
– reference: 11819806 - World J Gastroenterol. 2001 Jun;7(3):431-4
– reference: 16100946 - Cancer Invest. 2005;23(4):338-51
– reference: 12118264 - Rev Hosp Clin Fac Med Sao Paulo. 2002 May-Jun;57(3):89-92
– reference: 2369087 - Anticancer Res. 1990 May-Jun;10(3):703-8
– reference: 11984734 - Gastric Cancer. 2000 Dec;3(4):177-186
– reference: 18821070 - Adv Ther. 2008 Oct;25(10):1075-84
– reference: 22387886 - Eur J Gastroenterol Hepatol. 2012 Jun;24(6):605-12
– reference: 14605576 - Dis Colon Rectum. 2003 Nov;46(11):1538-44
– reference: 8903494 - Eur J Surg Oncol. 1996 Oct;22(5):505-7
– reference: 16033052 - Anticancer Res. 2005 May-Jun;25(3A):1507-15
– reference: 19579599 - Hepatogastroenterology. 2009 Mar-Apr;56(90):361-6
– reference: 1603581 - Orv Hetil. 1992 May 24;133(21):1301-4, 1307
– reference: 11154168 - J Clin Gastroenterol. 2001 Jan;32(1):41-4
– reference: 20396541 - Cancer Res Treat. 2004 Jun;36(3):178-81
– reference: 15362797 - Hepatogastroenterology. 2004 Sep-Oct;51(59):1544-7
– reference: 19688060 - Cancer Res Treat. 2008 Mar;40(1):16-21
– reference: 11274010 - Clin Chem. 2001 Apr;47(4):624-30
– reference: 15383868 - World J Surg. 2004 Jul;28(7):680-5
– reference: 8869281 - J Pathol. 1996 Aug;179(4):358-69
– reference: 7690061 - Int J Biol Markers. 1993 Apr-Jun;8(2):88-93
– reference: 8472349 - Clin Chem. 1993 Apr;39(4):561-77
– reference: 14520526 - Gastric Cancer. 2003;6(3):142-5
– reference: 11957811 - Pol Merkur Lekarski. 2002 Jan;12(67):77-80
– reference: 18375392 - J Biol Chem. 2008 Jun 6;283(23):15647-55
– reference: 19413512 - Annu Rev Biomed Eng. 2009;11:177-202
– reference: 10678558 - Jpn J Clin Oncol. 1999 Nov;29(11):550-5
– reference: 22810477 - Dis Colon Rectum. 2012 Aug;55(8):900-6
– reference: 15627885 - Tumour Biol. 2004 Sep-Dec;25(5-6):228-34
– reference: 14575569 - Zhonghua Zhong Liu Za Zhi. 2003 Sep;25(5):457-60
– reference: 18439085 - Asian Pac J Cancer Prev. 2008 Jan-Mar;9(1):97-100
– reference: 18942720 - J Surg Oncol. 2009 Jan 1;99(1):65-70
SSID ssj0000883648
Score 2.2980475
Snippet To determine the clinical serum levels of carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9), individually and in combination, for the...
Objective:To determine the clinical serum levels of carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9), individually and in combination, for...
SourceID doaj
pubmedcentral
wanfang
proquest
pubmed
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 148
SubjectTerms carbohydrate antigen 19-9, human
Carcinoembryonic antigen
Original
Receiver operating characteristic curve
sensitivity and specificity
SummonAdditionalLinks – databaseName: Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3daxQxEA9SaPFF6vdVK1H6oODazeb78VxailAFsdC3JZ_nyZErdz2KffM_d5JdzzsUfPF1Z0N285tMZpjJbxA6qp3wRtSy0oLpiglKKltHUjVUmkAlJTTk28jnH8XZBftwyS83Wn3lmrCeHrhfuGPuISCI0YOyBOaCsYS4nFyK4OhaEWO2vnDmbQRTxQYrRUVpnQVCXlHNyB46AgshmZbH38oGe7cW5Qov2nOd8oG7_28O5591k7s3JkWTJhtH0uk-ujf4knjc_8N9dCekB2jvfMiWP0Q_2t_U3rjwyOJ5xO3JGJvkcTsmutJ4mnDIrQzArpjZWzwxuZGHK29kQuuEXdaLxRJP11e3Zt-LGEaCukJkXcDFrz9_arFbLWAuMzCdvHmELk5PvrRn1dByofKNIqyyyjKuhKSmJkYGF8B_8UpG5ax2RCsIHlXjjAEvQooY4Gw3jdE-MM84MQ2jj9FOmqfwFOHIZaauN6yOigUhdc4ZcqEbp7yy1I7Q-7zQ3VXPqtFlnuvyANDvBvS7f6E_Qi9_wdTBvsjJDpPCfLWEkAbCfvDGaj5CT3rY1lMVEkY4hkdIbgG69S3bkjT9Wri3qRI1ZTDy1QB9N-z5ZXc7uZ3NXBeyMtWZyOzgf_zhM3S3KR04clnbc7RzvViFQ_CDru2LovI_AaIGA6M
  priority: 102
  providerName: Directory of Open Access Journals
Title Comparative study of CEA and CA19-9 in esophageal, gastric and colon cancers individually and in combination (ROC curve analysis)
URI https://www.ncbi.nlm.nih.gov/pubmed/24379990
https://www.proquest.com/docview/1490738905
https://d.wanfangdata.com.cn/periodical/zgzllc-e201303004
https://pubmed.ncbi.nlm.nih.gov/PMC3860340
https://doaj.org/article/5d998ffd053e4ceab11c7395f758b6ff
Volume 10
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbGJqa9IO6US2XQHkAiWxw7vjyhNrSakDrQRKW9RY5jl6IoHekq2N745xw7aaFiD4inSElsRz4Xny_H_g5Ch7HhpeaxiBRnKmKckqiIHYkSKrSlghJq_WnkySk_mbIP5-n5Dlpva-4mcHkjtPP1pKZNdfTj29U7MHiIX48EU-L4a7AXwHoqjahiHvUR2lKXprfQHqxRwhd1mHSBf_DRUlIeSmttWu2jw3_p0LMHew6_1ov7LWw3xaZ_b7G8_V3XTtezP1av8V10pws78aDVk3tox9b30f6kS6w_QD-z3yzgOFDO4oXD2WiAdV3ibEBUpPC8xtZXPQAXpKu3eKZ9zQ8T3vDc1zU2XoWaJZ5vTnlVV-ExtATNBhAe9AC_PvuYYbNqYCzdkaK8eYim49Hn7CTqqjNEZSIJiwpZsFRyQXVMtLDGQqhTSuGkKZQhSgLOlInRGgIOwZ2FMEAnWpWWlSwlGubwEdqtF7V9grBLhWe51yx2klkulE8vplwlRpayoEUPDf1E5xctAUfuKbHDjUUzyzsLy9MSkKNzJXgVy4zVBSHGZyEdIKKCO9dDL9diysGEfF5E13axWgL6UeDopIrTHnrcim0z1FrWPSS2BLr1LdtP6vmXQNNNJY8pg5avOtHna-3Or2fXVWVy6_Uq9pxnT_-7-2foIAkVOvy2t-do97JZ2RcQJ10WfbQ3GL4fjuE6HJ1-OuuH_w39YAi_AB3CEYE
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comparative+study+of+CEA+and+CA19-9+in+esophageal%2C+gastric+and+colon+cancers+individually+and+in+combination+%28ROC+curve+analysis%29&rft.jtitle=Cancer+biology+%26+medicine&rft.au=Bagaria%2C+Bhawna&rft.au=Sood%2C+Sadhna&rft.au=Sharma%2C+Rameshwaram&rft.au=Lalwani%2C+Soniya&rft.date=2013-09-01&rft.pub=Chinese+Anti-Cancer+Association&rft.issn=2095-3941&rft.volume=10&rft.issue=3&rft.spage=148&rft.epage=157&rft_id=info:doi/10.7497%2Fj.issn.2095-3941.2013.03.005&rft_id=info%3Apmid%2F24379990&rft.externalDocID=PMC3860340
thumbnail_s http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Fzgzllc-e%2Fzgzllc-e.jpg